Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048386 · ClinicalTrials.gov registry record · Phase 1
Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy
A Phase 1 study of Neuroblastoma, sponsored by Malcolm Brenner.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT00048386: Completed Phase 1 study of Neuroblastoma, sponsored by Malcolm Brenner.
NCT00048386 is a Phase 1 study of Neuroblastoma that has completed, run by Malcolm Brenner. The registered enrollment target is 13 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00048386, a Phase 1 study of Neuroblastoma, has completed, sponsored by Malcolm Brenner.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
PRIMARY OBJECTIVE To determine the percentage of patients with high risk neuroblastoma in first or subsequent partial response or better, or with microscopic residual bone marrow disease, who demonstrate an immunological anti-tumor response at any time during, and for up to 12 months from initiation of, treatment with subcutaneous injections of autologous neuroblastoma cells, genetically modified by adenoviral vectors to secrete interleukin-2 (IL-2) (autologous neuroblastoma vaccine) SECONDARY OBJECTIVES 1. To determine the toxicity of the autologous neuroblastoma vaccine given according to this schedule 2. To obtain preliminary data on the effect of vaccine administration on progression-free survival from high-risk neuroblastoma
Conditions Studied
Interventions
- BIOLOGICAL autologous neuroblastoma vaccine
Study Locations (1)
Texas
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 1999-11 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
What the finished NCT00048386 record still lists
NCT00048386 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which autologous neuroblastoma vaccine is the first listed.
NCT00048386 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00048386 about?
NCT00048386 is a clinical study titled "Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy". PRIMARY OBJECTIVE To determine the percentage of patients with high risk neuroblastoma in first or subsequent partial response or better, or with microscopic residual bone marrow disease, who demonstrate an immunological anti-tumor response at any time during, and for up to 12 months from initiation...
What is the current status of trial NCT00048386?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 1999-11. Estimated completion is 2009-10.
What conditions does trial NCT00048386 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT00048386?
The interventions under investigation include: autologous neuroblastoma vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00048386?
This trial is sponsored by Malcolm Brenner, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00048386 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00048386's enrollment target sits among peer trials
13 84th of 94 higher than 9 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia